Alvotech (ALVO)
13.33
0.11 (0.83%)
At close: Jan 14, 2025, 3:59 PM
12.00
-9.98%
Pre-market Jan 15, 2025, 04:16 AM EST
undefined% (undefined)
| Bid | 12 |
| Market Cap | 4.02B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.85 |
| PE Ratio (ttm) | -7.21 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 13.3 |
| Volume | 161,262 |
| Avg. Volume (20D) | 116,406 |
| Open | 13.16 |
| Previous Close | 13.22 |
| Day's Range | 13.16 - 13.41 |
| 52-Week Range | 9.15 - 18.00 |
| Beta | undefined |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque...
Sector Healthcare
IPO Date Jun 16, 2022
Employees 999
Stock Exchange NASDAQ
Ticker Symbol ALVO
Website https://www.alvotech.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 35.03% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Alvotech is scheduled to release its earnings on Mar 19, 2025,
during market hours.
Analysts project revenue of $87.50M, reflecting a 63.89% YoY growth and earnings per share of -0.01, making a -99.18% decrease YoY.
Analysts project revenue of $87.50M, reflecting a 63.89% YoY growth and earnings per share of -0.01, making a -99.18% decrease YoY.
2 months ago ·
Source
-1.89%
Alvotech shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago ·
Source
-3.47%
Alvotech shares are trading lower after the company announced an offering of up to 1,789,087 shares by the selling shareholder.
